Linkedin Labtau 

HIFU Gynecology

Project Description

Treatment of posterior deep invasive endometriosis with transrectal HIFU

Posterior deep invasive endometriosis (DIE) includes lesions of the utero-sacral ligaments, torus uterinum and the rectosigmoid. The rectosigmoid lesions are associated with painful symptoms that can alter quality of life. A phase I, non-controlled, prospective monocentric clinical study was performed with FocalOne in order to assess the feasibility, the safety and the clinical efficacy of the FocalOne in patients presenting posterior DIE with rectal involvement. On eleven patients, it was demonstrated that HIFU can be an interesting alternative to surgery for the treatment of posterior DIE. A significant improvement of the MOS-SF36 was observed with an increase of both Physical Composite Score and Mental Composite Score at  6 months. No significant complications occurred during and after the procedure.

Treatment of the placental unit pathologies using HIFU

The aim of this research project is to demonstrate the feasibility and efficacy of high-intensity focused ultrasound (HIFU) to treat placental pathologies. A HIFU device that uses a toroidal transducer was developed for treating twin-to-twin transfusion syndrome (TTTS) and placenta accreta. Regarding the treatment of TTTS fetoscopy is the gold standard since it increases survival rate. However, it is also considered invasive and responsible for fetal and maternal complications that can affect neonatal outcome. These complications are partially associated with the opening of the amniotic cavity. A completely non-invasive treatment that could occlude deep anastomoses would prevent the risks of invasive fetoscopy while offering the potential for more effective therapy. We previously developed a toroidal HIFU transducer that enables the destruction of large tissue volumes. In a recent study, we demonstrated the ability to induce lesions in human placenta using this toroidal-shaped transducer without damaging intervening tissues.The effectiveness of this HIFU device applied to the perfused placental unit must be studied in more thoroughly before starting a clinical trial.

Figures

Treatment of the placental unit pathologies using HIFU

Staff

LabTau Staff

  • David Melodelima (DR INSERM, PI)
  • Cyril Huissoud (PU-PH HCL, co-PI)
  • Jonathan Caloone (PhD)
  • Gil Dubernard
  • Charles André Philip
  • Cyril Lafon
  • Françoise Chavrier
  • Jean-Yves Chapelon

Collaborations

  • Hospices Civiles de Lyon, Croix Rousse UniversityHospital
  • EDAP - TMS

Publications